10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 38.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,318 shares of the company’s stock after purchasing an additional 4,258 shares during the quarter. Axxcess Wealth Management LLC’s holdings in 10x Genomics were worth $346,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in 10x Genomics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock worth $341,581,000 after buying an additional 90,204 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of 10x Genomics by 604.9% during the 2nd quarter. SG Americas Securities LLC now owns 101,344 shares of the company’s stock valued at $1,971,000 after purchasing an additional 86,967 shares in the last quarter. Lecap Asset Management Ltd. acquired a new position in 10x Genomics in the third quarter worth approximately $877,000. Marshall Wace LLP acquired a new position in shares of 10x Genomics in the 2nd quarter valued at $689,000. Finally, Benjamin F. Edwards & Company Inc. increased its position in shares of 10x Genomics by 10,124.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 44,785 shares of the company’s stock worth $871,000 after acquiring an additional 44,347 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Price Performance

TXG opened at $14.91 on Thursday. The business’s 50-day moving average price is $18.93 and its two-hundred day moving average price is $20.65. 10x Genomics, Inc. has a 1 year low of $14.02 and a 1 year high of $57.90.

10x Genomics (NASDAQ:TXG) last released its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. The business had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same period last year, the business earned ($0.51) earnings per share. Equities analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. UBS Group lowered their target price on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. The Goldman Sachs Group lowered their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research note on Wednesday, October 30th. Stephens reiterated an “overweight” rating and set a $30.00 target price on shares of 10x Genomics in a research note on Thursday, October 10th. Citigroup reduced their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. Finally, Bank of America decreased their target price on shares of 10x Genomics from $36.00 to $25.00 and set a “neutral” rating on the stock in a research report on Thursday, July 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, 10x Genomics currently has a consensus rating of “Moderate Buy” and an average price target of $29.19.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 6,749 shares of 10x Genomics stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $152,054.97. Following the completion of the transaction, the chief executive officer now directly owns 882,467 shares of the company’s stock, valued at $19,881,981.51. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other 10x Genomics news, CFO Justin J. Mcanear sold 2,961 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $66,711.33. Following the sale, the chief financial officer now directly owns 143,242 shares of the company’s stock, valued at $3,227,242.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Serge Saxonov sold 6,749 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $152,054.97. Following the sale, the chief executive officer now directly owns 882,467 shares of the company’s stock, valued at $19,881,981.51. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,061 shares of company stock valued at $316,794. Insiders own 10.03% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.